Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

New medicines have made weight loss easier than ever. But if you also want health and happiness, make these seven psychology ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

The review that pooled the results of 11 studies has found that people started regaining weight two months after stopping the ...